

Thesis, Figures 3–7C and 3–8A, left column, and reusing them after flipping horizontally and vertically as lanes 12–18 in the same GAPDH panel in the same figures to represent samples from COPD patients

• **JCI 2011**

- by trimming Western blot panels from:
 - Figure 2D, reusing and relabeling in Figure 4A to represent different samples
 - Supplemental Figure 1A, reusing and relabeling in Figure 4A to represent different samples
 - Figure 3F, reusing and relabeling Figure 3B, bottom panel, in *PLoS Comp Biol.* 2012
 - Figure 9B and the Ph.D. Thesis Figure 4–9H, bottom panel, lanes 1–5, and reusing them in Figure 4–8C, lanes 4–8, in the Ph.D. Thesis, to represent different samples
 - Figure 9B and the Ph.D. Thesis, Figure 4–9H, middle panel, lanes 1–3, and reusing them in Figure 4–8C, middle panel, lanes 2–4, in the Ph.D. Thesis, to represent different samples
 - Figure 9D and the Ph.D. Thesis, Figure 4–9I, top panel, lanes 1–4, and reusing them after flipping horizontally in Figure 4–8C, top panel, lanes 1–4, in the Ph.D. Thesis, to represent different samples
- by trimming negative DNA gel images from:
 - Figure 2A, reversing and reusing the positive image as Western blot images in:
 - Figure 3B
 - Supplemental Figure 3A
 - Figure 3G, reversing and reusing the positive image as Western blots in different panels in Figure 3B in *PLoS Comp Biol.* 2012

Dr. Malhotra entered into a Voluntary Exclusion Agreement (Agreement) and agreed for a period of four (4) years, beginning on October 1, 2019:

(1) To exclude herself voluntarily from any contracting or subcontracting with any agency of the United States Government and from eligibility for or involvement in nonprocurement programs of the United States Government referred to as “covered transactions” pursuant to HHS’ Implementation (2 CFR part 376) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the “Debarment Regulations”); and

(2) to exclude herself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board,

and/or peer review committee, or as a consultant.

Elisabeth A. Handley,

Interim Director, Office of Research Integrity.

[FR Doc. 2019–24691 Filed 11–13–19; 8:45 am]

BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Findings of research misconduct have been made against Dr. Sudhakar Yakkanti (Respondent) (formerly named Sudhakar Akulapalli),¹ former staff scientist and Director of the Cell Signaling, Retinal & Tumor Angiogenesis Laboratory, Boys Town National Research Hospital (BTNRH). Respondent engaged in research misconduct in research supported by U.S. Public Health Service (PHS) funds, specifically, National Cancer Institute (NCI), National Institutes of Health (NIH), grant R01 CA143128, National Eye Institute (NEI), NIH, grants R01 EY018179 and R01 EY16695, and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, grants R01 DK055000, R01 DK055001, R01 DK062987, and R01 DK051711. The administrative actions, including debarment for a period of five (5) years, were implemented beginning on August 24, 2019, and are detailed below.

FOR FURTHER INFORMATION CONTACT:

Elisabeth A. Handley, Interim Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 240, Rockville, MD 20852, (240) 453–8200.

SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

Dr. Sudhakar Yakkanti, Boys Town National Research Hospital: Based upon the evidence and findings of an investigation report by BTNRH and additional information obtained by ORI during its oversight review of the BTNRH investigation, ORI found that Dr. Sudhakar Yakkanti, former staff scientist and Director of the Cell Signaling, Retinal & Tumor Angiogenesis Laboratory, BTNRH, engaged in research misconduct in research supported by PHS funds,

¹ The Respondent changed his name from Sudhakar Akulapalli to Sudhakar Yakkanti during the BTNRH inquiry.

specifically, NCI, NIH, grant R01 CA143128, NEI, NIH, grants R01 EY018179 and R01 EY16695, and NIDDK, NIH, grants R01 DK055000, R01 DK055001, R01 DK062987, and R01 DK051711.

ORI found by a preponderance of the evidence that Respondent intentionally, knowingly, or recklessly falsified and/or fabricated figures in the following eight (8) unfunded NIH grant applications, one (1) funded NIH grant application, seven (7) publications, and two (2) unpublished manuscripts:

- R01 CA115763–01A2 submitted to NCI, NIH (unfunded)
- R21 CA155796–01 submitted to NCI, NIH (unfunded)
- R01 CA166195–01 submitted to NCI, NIH (unfunded)
- R01 CA143128–01 submitted to NCI, NIH (unfunded)
- R01 CA143128–04 submitted to NCI, NIH (unfunded)
- R01 EY020539–01 submitted to NEI, NIH (unfunded)
- R01 EY020539–01A1 submitted to NEI, NIH (unfunded)
- R01 EY024967–01 submitted to NEI, NIH (unfunded)
- R01 CA143128–01A1 submitted to NCI, NIH (funded)
- *Biochemistry* 2000;39(42):12929–12938 (hereafter referred to as “*Biochem* 2000”)
- *Proc. Natl. Acad. Sci. U.S.A.* 2003;100(8):4766–4771 (hereafter referred to as “*PNAS* 2003”)
- *The Journal of Clinical Investigation* 2005;115(10):2801–2810 (hereafter referred to as “*JCI* 2005”)
- *Invest. Ophthalmol. Vis. Sci.* 2009;50(10):4567–4575 (hereafter referred to as “*IOVS* 2009”)
- *Pharmaceutical Research* 2008;25(12):2731–2739 (hereafter referred to as “*Pharm Research* 2008”)
- *Scientific Reports* 2014;4(4136):1–9 (hereafter referred to as “*Sci Reports* 2014”)
- *Current Eye Res.* 2010 Jan;35(1):44–55 (hereafter referred to as “*CER* 2010”)
- Tumstatin inhibits Choroidal Neovascularization by Inhibiting MMP–2 activation *in-vitro* and *in vivo*. Submitted to *Molecular Vision* on February 7, 2011 (hereafter referred to as “*Mol Vis* Sub 2011”) (unpublished)
- Inhibitory Effect of Tumstatin on Corneal Neovascularization Both *In-vitro* and *In-vivo*. Submitted to *Journal of Clinical & Experimental Ophthalmology* on January 16, 2011 (hereafter referred to as “*JCEO* Sub 2011”) (unpublished)

Specifically, ORI found by a preponderance of the evidence that

Respondent engaged in research misconduct by intentionally, knowingly, or recklessly:

- falsifying an image from an *in vivo* choroidal neovascularization (CNV) experiment by falsely relabeling an image representing results from an experiment with the anti-angiogenic molecule arresten ($\alpha 1$ NC1) to represent results from a different CNV experiment with a different anti-angiogenic molecule, hexastatin ($\alpha 6$ NC1) in Figure 9A (right panel) of grant application R01 CA166195–01
- falsifying an image from an *in vivo* CNV experiment by falsely relabeling an image representing results from an experiment with the anti-angiogenic molecule hexastatin ($\alpha 6$ NC1) to represent results from different CNV experiments with different anti-angiogenic molecules:
 - Arresten ($\alpha 1$ NC1) in Figure 10A (right panel) of grant application R01 EY020539–01A1
 - tumstatin ($\alpha 3$ NC1) in Figure 6A (right panel) of *Mol Vis* Sub 2011
- falsifying and/or fabricating bar graphs in Figure 9B of grant application R01 CA166195–01, which was based on the falsified image in Figure 9A (right panel) of grant application R01 CA166195–01
- falsifying and/or fabricating bar graphs in Figure 6B of *Mol Vis* Sub 2011, which was based on the falsified image in Figure 6A (right panel) of *Mol Vis* Sub 2011
- falsifying and/or fabricating bar graphs in Figure 10B of grant application R01 EY020539–01A1, which was based on the falsified image in Figure 10A of grant application R01 EY020539–01A1
- falsifying microscope images of endothelial tube formation assays by labeling one image as two different experiments:
 - A control in an experiment performed in Human umbilical vein endothelial cells (HUVECs) in Figure 1D (first panel) of grant application R21 CA155796–01
 - a control in an experiment performed in mouse choroidal endothelial cells (MCECs) in Figure 2B (first panel) of grant application R01 EY020539–01A1
- falsifying microscope images of endothelial tube formation assays by reusing and falsely labeling one image as three different experiments:
 - HUVECs treated with 0.5 μ M hexastatin ($\alpha 6$ (IV)NC1) in Figure 1D (third panel) of grant application R21 CA155796–01
 - MCECs treated with 0.5 μ M arresten ($\alpha 1$ (IV)NC1) in Figure 2B (second panel) of grant application R01 EY020539–01A1
 - MCECs treated with 1.0 μ M tumstatin ($\alpha 3$ (IV)NC1) in Figure 2C (bottom right panel) of *Mol Vis* Sub 2011
- falsifying Western blot images by reusing and falsely labeling one image as four different experiments:
 - The protein band FAK from HUVECs treated with hexastatin ($\alpha 6$ (IV)NC1) in Figure 3A (bottom panel) of grant application R21 CA155796–01 and Figure 4A (bottom panel) of grant application R01 CA166195–01
 - the protein band FAK from MCECs treated with arresten ($\alpha 1$ (IV)NC1) in Figure 5A (bottom panel) of grant application R01 EY020539–01A1
 - the protein band Raf from HUVECs treated with rh-Endo in Figure 5A (bottom panel) of *PNAS* 2003
 - the protein band FAK from mouse retinal pigmented epithelial cell (MRPECs) treated with arresten ($\alpha 1$ (IV)NC1) in Figure 5B (bottom panel) of grant application R01 EY020539–01 and in Figure 7B (bottom panel) of *IOVS* 2009
- falsifying Western blot images by reusing and falsely labeling one image as two different experiments:
 - HUVECs treated with rh-Endo in Figure 5D (middle panel) of *PNAS* 2003
 - mouse retinal endothelial cells (MRECs) treated with arresten ($\alpha 1$ (IV)NC1) in Figure 7C (top panel) of *IOVS* 2009
- falsifying Western blot images by reusing and falsely labeling one image as two different experiments:
 - HUVECs treated with hexastatin ($\alpha 6$ (IV)NC1) in Figure 3C (top panel) of grant application R21 CA155796–01
 - MCECs treated with arresten ($\alpha 1$ (IV)NC1) in Figure 5B (top panel) of grant application R01 EY020539–01A1
- falsifying Western blot images by reusing and falsely labeling one image as two different experiments:
 - HUVECs treated with hexastatin ($\alpha 6$ (IV)NC1) in Figure 3C (bottom panel) of grant application R21 CA155796–01
 - MCECs treated with arresten ($\alpha 1$ (IV)NC1) in Figure 5B (bottom panel) of grant application R01 EY020539–01A1
- falsifying Western blot images by reusing and falsely labeling one image as two different experiments:
 - HUVECs treated with hexastatin ($\alpha 6$ (IV)NC1) in Figure 3D (top panel) of grant application R21 CA155796–01
 - MCECs treated with arresten ($\alpha 1$ (IV)NC1) in Figure 5C (top panel) of grant application R01 EY020539–01A1
- falsifying Western blot images by reusing and falsely labeling one image as two different experiments:
 - HUVECs treated with hexastatin ($\alpha 6$ (IV)NC1) in Figure 5C (top panel) of grant application R01 CA143128–01 and Figure 2B (top panel) of grant application R01 CA143128–01A1
 - the protein band Cox-2 from MCECs treated with arresten ($\alpha 1$ (IV)NC1) in Figure 5C (top panel) of grant application R01 CA143128–04 and Figure 8B (top panel) of R01 EY024967–01
- falsifying Western blot images by reusing and falsely labeling one image as two different experiments:
 - The protein band eIF2 α 51A in Figure 1A (lanes 3–5) of *Biochem* 2000
 - the protein band tumstatin ($\alpha 3$ (IV)NC1) in Figure 2 (lanes 2–4) of *Pharm Research* 2008
- falsifying Western blot images by reusing and falsely labeling one image as two different experiments:
 - The protein band active MMP–2 in Figure 10D (top panel, lanes 1–4) of grant application R01 CA115763–01A2, Figure 10B of grant application R01 CA143128–01, Figure 10B (third panel, lanes 1–4) of grant application R01 CA143128–01A1, and Figure 7D (third panel, lanes 1–4) of grant application R01 EY020539–01A1
 - the protein band arresten ($\alpha 1$ (IV)NC1) in Figure 3C (lanes 3–6) of *Sci Reports* 2014, Figure 6D (lanes 3–6) of grant application R01 CA143128–04, and Figure 9D (lanes 3–6) of grant application R01 EY024967–01
- falsifying Western blot images by reusing and falsely labeling one image as three different experiments:
 - HUVECs treated with hexastatin ($\alpha 6$ (IV)NC1) in Figure 3D (bottom panel) of grant application R21 CA155796–01, and Figure 4A (bottom panel) of grant application R01 CA166195–01
 - MCECs treated with arresten ($\alpha 1$ (IV)NC1) in Figure 5C (bottom panel) of grant application R01 EY020539–01A1
 - the protein band FAK(P) from HUVECs treated with rh-Endo in Figure 4A (top panel) of *PNAS* 2003

- The protein band Raf from mouse lung endothelial cells (MLECs) at the time points 0, 5, 10, 20, and 30 minutes in Figure 5A (bottom panel, lanes 1–5) of *JCI* 2005
 - the protein band FAK(P) from MRECs at the time points 20 and 40 minutes in Figure 7A (top panel, lanes 2 and 4) of *IOVS* 2009 and Figure 5A (top panel, lanes 2 and 4) of grant application R01 EY020539–01
 - the protein band FAK from MRECs at the time points 0, 20, 40, and 40 minutes in Figure 7A (bottom panel, lanes 1–5) of *IOVS* 2009 and Figure 5A (bottom panel, lanes 1–5) of grant application R01 EY020539–01
 - falsifying images of corneas by reusing and falsely labeling one image as two different experiments:
 - CNV cornea treated with arresten ($\alpha 1(IV)NC1$) in Figure 13 (right panel) of grant application R01 EY020539–01
 - CNV cornea treated with tumstatin ($\alpha 3(IV)NC1$) in Figure 3A (right panel) of *JCEO* Sub 2011
 - falsifying images of corneal sections by reusing and falsely labeling one image as two different experiments:
 - CNV cornea treated with arresten ($\alpha 1(IV)NC1$) in Figure 14 (right panel) of grant application R01 EY020539–01
 - CNV cornea treated with tumstatin ($\alpha 3(IV)NC1$) in Figure 4 (right panel) of *JCEO* Sub 2011
 - falsifying endothelial cell migration assays by reusing and falsely labeling one image as two different experiments:
 - MRECs treated with vascular endothelial growth factor (VEGF) and arresten ($\alpha 1(IV)NC1$) in Figure 2A (top right panel) of *IOVS* 2009 and Figure 2 (top right panel) of grant application R01 EY020539–01
 - HUVECs treated with only VEGF in Figure 1C (middle panel) of grant application R21 CA155796–01 and Figure 2C (second panel) of grant application R01 CA166195–01
 - falsifying endothelial cell migration assays by reusing and falsely labeling one image as two different experiments:
 - MRECs treated with VEGF in Figure 2A (top middle panel) of *IOVS* 2009 and Figure 2 (top middle panel) of grant application R01 EY020539–01
 - MRECs treated with basic fibroblast growth factor (bFGF) in Figure 3A (second panel) of *CER* 2010
 - falsifying endothelial cell migration assays by reusing and falsely labeling one image as three different experiments:
 - MRECs treated with bFGF and arresten ($\alpha 1NC1$) in Figure 3A (fourth panel) of *CER* 2010
 - MRECs treated with VEGF and arresten ($\alpha 1NC1$) in Figure 2A (bottom middle panel) of *IOVS* 2009 and Figure 2 (bottom middle panel) of grant application R01 EY020539–01
 - falsifying endothelial cell migration assays by reusing and falsely labeling one image as two different experiments:
 - MRECs treated with bFGF and 10 μ g/ml arresten ($\alpha 1NC1$) in Figure 3A (fifth panel) of *CER* 2010
 - HUVECs treated with VEGF and 0.5 μ M hexastatin ($\alpha 6NC1$) in Figure 1C (last panel) of grant application R21 CA155796–01
 - HUVECs treated with VEGF and 0.25 μ M hexastatin ($\alpha 6NC1$) in Figure 2C (third panel) of grant application R01 CA166195–01
- The following administrative actions have been implemented, beginning on August 24, 2019:
- (1) Respondent is debarred for a period of five (5) years from eligibility for any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement programs of the United States Government referred to as “covered transactions” pursuant to HHS’ Implementation (2 CFR part 376 *et seq.*) of Office of Management and Budget (OMB) Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the “Debarment Regulations”);
 - (2) Respondent is prohibited from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of five (5) years; and
 - (3) in accordance with 42 CFR 93 §§ 93.407(a)(1) and 93.411(b), HHS will send a notice of the findings and of the need for correction or retraction to the pertinent journals for each of the following:
 - *Biochemistry* 2000;39(42):12929–12938
 - *Proc. Natl. Acad. Sci. U.S.A.* 2003;100(8):4766–4771
 - *The Journal of Clinical Investigation* 2005;115(10):2801–2810
 - *Invest. Ophthalmol. Vis. Sci.* 2009;50(10):4567–4575
 - *Pharmaceutical Research* 2008;25(12):2731–2739
- *Scientific Reports* 2014;4(4136):1–9
 - *Current Eye Res.* 2010 Jan;35(1):44–55
- Elisabeth A. Handley,**
Interim Director, Office of Research Integrity.
[FR Doc. 2019–24689 Filed 11–13–19; 8:45 am]
- BILLING CODE 4150–31–P**
-
- DEPARTMENT OF HEALTH AND HUMAN SERVICES**
- National Institutes of Health**
- National Center For Advancing Translational Sciences; Notice of Closed Meeting**
- Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.
- The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
- Name of Committee:* National Center for Advancing Translational Sciences Special Emphasis Panel; CTSA.
- Date:* January 24, 2020.
- Time:* 8:00 a.m. to 5:00 p.m.
- Agenda:* To review and evaluate grant applications.
- Place:* Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852.
- Contact Person:* Victor Henriquez, Ph.D., Scientific Review Officer, Office of Scientific Director, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, 6701 Democracy Blvd., Democracy 1, Room 1080, Bethesda, MD 20892–4878. 301–435–0813, henriqvu@mail.nih.gov.
- (Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)
- Dated: November 7, 2019.
- Melanie J. Pantoja,**
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019–24677 Filed 11–13–19; 8:45 am]
- BILLING CODE 4140–01–P**